Observed Signal · Sep 1, 2026 · corporate_event · Source: SEC API · Impact: 3.4/5
8-K Financial Filing Analysis for Humana (2026-09-01)
On September 1, 2026, Humana Inc. filed a Form 8-K announcing that senior management will reaffirm the company's full-year 2026 financial guidance during upcoming investor and analyst conferences throughout September. Humana continues to project full-year 2026 diluted GAAP EPS of at least $6.52 and non-GAAP Adjusted EPS of at least $9.00, maintaining the outlook originally issued on July 29, 2026. Furthermore, the company clarified that it will withhold commentary regarding the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028) until final data is officially published by the Centers for Medicare and Medicaid Services (CMS) in October.
Reaffirming annual EPS targets provides near-term earnings visibility and stability ahead of investor conferences, while deferring commentary on critical CMS Star Ratings keeps market attention focused on the upcoming October regulatory release.
Track Humana Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Humana reaffirmed its full-year 2026 financial outlook, maintaining targets for diluted GAAP EPS of at least $6.52 and Adjusted EPS of at least $9.00.
- The guidance reconciliation reflects net adjustments of $2.48 per share, including put/call valuations ($1.47), value creation initiatives ($1.27), intangible amortization ($0.30), impairments ($0.17), and tax impacts ($(0.73)).
- Management explicitly deferred all commentary on 2027 Medicare Advantage Star Ratings (Bonus Year 2028) until CMS releases final ratings in October 2026.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
8-K Financial Filing Analysis for Humana (2026-10-09)
Humana Inc. announced that it has exceeded its goal of Top Quartile results for the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028), based on final data released by the Centers for Medicare and Medicaid Services (CMS) on October 8, 2026. Top Quartile performance is defined as Stars revenue per member per month (PMPM) at least 10% above the peer group median. While anticipating that a portion of the 2028 bonus outperformance will be one-time in nature, Humana expects to utilize the resulting financial benefit for one-time investments and capital returns to shareholders. Concurrently, the company reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 and announced a virtual investor update scheduled for December 10, 2026.
8-K Financial Filing Analysis for Humana (2026-10-13)
On October 13, 2026, Humana Inc. announced a new joint venture arrangement with funds managed by HPS Investment Partners, a subsidiary of BlackRock, Inc., to manage and operate its CenterWell Senior Primary Care clinic network. This arrangement replaces CenterWell's existing joint venture with Welsh, Carson, Anderson & Stowe (WCAS), with BlackRock acquiring WCAS's equity stake under modified terms. Notably, the new JV eliminates the previous put option held by WCAS, resulting in an expected significant reduction in balance sheet liabilities and a lower overall cost of capital. Concurrently, Humana reaffirmed its FY 2026 Adjusted EPS guidance of at least $9.00.
8-K Financial Filing Analysis for UnitedHealth Group (2026-10-13)
On October 13, 2026, UnitedHealth Group Incorporated filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing the release of its third quarter 2026 financial results via an accompanying press release and related materials furnished as Exhibits 99.1 and 99.2. The filing serves as the formal SEC notification of UnitedHealth Group's Q3 2026 earnings release, although specific financial statements and detailed operational metrics were furnished directly in the referenced exhibits rather than embedded within the text of the report.
Receive all future signals for Humana & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.